MGF

What is MGF?#

MGF (Mechano Growth Factor) is a naturally occurring peptide that represents the unique C-terminal E-domain of the IGF-1Ec splice variant in humans (IGF-1Eb in rodents). When skeletal muscle or other tissues are subjected to mechanical stress or damage, the IGF-1 gene undergoes alternative splicing to produce the IGF-1Ec transcript. This transcript encodes a precursor protein that contains a distinct 24-amino acid E-domain peptide not found in the predominant IGF-1Ea isoform.

The discovery of MGF emerged from the laboratory of Geoffrey Goldspink at University College London, who first characterized this splice variant and coined the term "Mechano Growth Factor" to describe its mechanosensitive expression pattern. The peptide was identified in the late 1990s and early 2000s through studies of IGF-1 gene expression in response to mechanical loading in rabbit and human skeletal muscle.

Mechanism of Action#

MGF functions as a locally acting tissue repair factor through a mechanism distinct from systemic IGF-1. While mature IGF-1 (the common 70-amino acid peptide encoded by exons 3 and 4) binds to the IGF-1 receptor (IGF-1R) to promote cell differentiation and growth, the MGF E-domain peptide has independent biological activity that does not require IGF-1R signaling.

The primary biological role of MGF appears to be the activation of quiescent satellite cells, the resident stem cells in skeletal muscle. Following mechanical stress or injury, MGF is expressed locally before the IGF-1Ea splice variant, creating a sequential signaling cascade:

1. Phase 1 - MGF expression: Immediately following damage or mechanical loading, the IGF-1Ec splice variant is upregulated. The MGF E-domain peptide activates quiescent satellite cells, stimulating their entry into the cell cycle and proliferation as myoblasts.

2. Phase 2 - IGF-1Ea expression: After the initial proliferative phase, the splicing pattern shifts to favor the IGF-1Ea variant. Mature IGF-1 then promotes differentiation and fusion of the expanded myoblast pool into mature myofibers, completing the repair process.

This temporal sequence positions MGF as the initiating signal for muscle repair, responsible for expanding the precursor cell pool before differentiation signals take over.

Biological Context#

The MGF E-domain is not unique to skeletal muscle. Expression of the IGF-1Ec splice variant has been documented in cardiac muscle following myocardial infarction, in brain tissue following ischemic injury, in bone following fracture, and in cartilage under mechanical loading. This suggests that the MGF signaling pathway may be a general tissue repair mechanism activated by mechanical stress or damage across multiple organ systems.

In skeletal muscle, MGF expression declines with aging. Studies have shown that older individuals have impaired upregulation of the IGF-1Ec splice variant in response to exercise, which may contribute to the age-related decline in muscle regenerative capacity (sarcopenia). This observation has generated interest in whether exogenous MGF peptide administration could restore regenerative signaling in aging muscle.

Conflicting Evidence#

It is important to note that MGF research is not without controversy. A 2014 study by Fornaro et al., published in the American Journal of Physiology, found that synthetic MGF peptide had no apparent effect on myoblast proliferation or primary muscle stem cells when tested under controlled conditions. The authors suggested that some previously reported effects may have been due to experimental conditions rather than direct MGF activity. This underscores the need for additional well-controlled studies to definitively establish MGF's biological mechanisms.

Current Status#

MGF remains a preclinical research compound with no approved therapeutic applications. It is not approved by any regulatory agency for human use. The peptide is prohibited by WADA under S2 (Growth Factors) for athletic use. Research continues in the areas of muscle regeneration, cardiac repair, neuroprotection, and bone healing, though the path from preclinical promise to clinical application has been slower than initially anticipated due to the peptide's extremely short half-life and conflicting results in some experimental systems.

Evidence Gaps and Limitations#

The current evidence base for MGF consists primarily of preclinical studies. Key limitations include:

• No completed randomized controlled trials in humans
• Most data derived from animal models, limiting direct translatability
• Conflicting results between research groups regarding biological activity
• Extremely short half-life (~minutes) limits practical therapeutic application
• Distinction between MGF E-domain peptide effects and full-length IGF-1Ec effects not fully resolved
• Long-term safety data in humans is not available
• Optimal dosing for human applications has not been established

Key Research Findings#

Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration, published in Endocrinology (Goldspink G, 2010; PMID: 20130113):

Comprehensive minireview by the discoverer of MGF, summarizing the evidence for MGF as a locally acting repair factor expressed through IGF-1 gene splicing in response to mechanical loading and tissue damage.

• MGF is expressed locally in response to mechanical overload and damage
• Acts independently of the IGF-1 receptor through an unidentified pathway
• Activates satellite cells for muscle repair initiation

Mechano Growth Factor E peptide (MGF-E) activates human muscle progenitor cells and induces an increase in their fusion potential at different ages, published in Mechanisms of Ageing and Development (Kandalla PK et al., 2011; PMID: 21354439):

Study demonstrating that synthetic MGF-E peptide activates human muscle progenitor cells from neonatal and young adult donors, increasing their proliferative lifespan and fusion potential. Effect diminished in cells from older donors.

• MGF-E peptide increased proliferative lifespan of human muscle progenitor cells
• Enhanced fusion potential (myogenic differentiation capacity)
• Age-dependent response with diminished effect in cells from older donors

Mechano growth factor (MGF) promotes proliferation and inhibits differentiation of porcine satellite cells (PSCs) by down-regulation of key myogenic transcriptional factors, published in Molecular and Cellular Biochemistry (Qin LL et al., 2012; PMID: 22875667):

Study showing that MGF promotes proliferation while inhibiting differentiation of porcine satellite cells through downregulation of myogenic transcription factors MyoD, myogenin, and MEF2C.

• MGF promoted satellite cell proliferation dose-dependently
• Inhibited premature differentiation by downregulating MyoD and myogenin
• MEF2C expression was also suppressed by MGF treatment

Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction, published in Heart, Lung and Circulation (Carpenter V et al., 2008; PMID: 17581790):

Preclinical study demonstrating that systemic MGF E-domain peptide administration following acute myocardial infarction preserved cardiac function and inhibited cardiomyocyte apoptosis in a mouse model.

• MGF preserved cardiac function post-MI in mice
• Reduced cardiomyocyte apoptosis
• Prevented pathological cardiac remodeling

Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain, published in Molecular Brain (Tang JJ et al., 2017; PMID: 28683812):

Study showing that MGF overexpression in aging mice increased proliferative cells in the hippocampal dentate gyrus and subventricular zone, promoting neurogenesis without altering post-mitotic maturation.

• Increased proliferative cells in dentate gyrus and SVZ
• Promoted neurogenesis at the proliferation stage
• Did not alter distribution of neurons at post-mitotic maturation stages

Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells, published in American Journal of Physiology - Endocrinology and Metabolism (Fornaro M et al., 2014; PMID: 24253050):

Contradictory study finding that synthetic MGF peptide had no significant effect on C2C12 myoblast proliferation or differentiation, and no effect on primary mouse muscle stem cells. Challenged the prevailing narrative of MGF biological activity.

• No significant effect on C2C12 myoblast proliferation
• No effect on primary mouse muscle stem cell behavior
• Failed to replicate previously reported proliferative effects

Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits, published in DNA and Cell Biology (Liu XH et al., 2010; PMID: 21057789):

Study demonstrating that MGF E-domain peptide promotes osteoblast proliferation in vitro and enhances bone defect healing in a rabbit model, supporting MGF's role in bone tissue repair.

• MGF-E peptide promoted osteoblast proliferation in vitro
• Enhanced bone defect healing in rabbit model
• New bone formation was accelerated compared to controls

Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls, published in Growth Hormone and IGF Research (Drs JA et al., 2015; PMID: 25466910):

Study characterizing biotechnologically produced full-length MGF using mass spectrometry for anti-doping purposes. Established reference standards and detection methodologies for identifying MGF misuse in sports.

• Established LC-MS/MS detection method for MGF
• Characterized full-length MGF reference material
• Identified unique fragmentation patterns for selective detection

Related Reading#

• MGF research studies and evidence
• MGF dosing protocols
• MGF side effects profile
• HGH 191AA research guide
• IGF-1 DES research guide